Imdelltra-Imfinzi combo shows 58% lower death risk than Imfinzi alone in lung cancer trial

The late-stage trial tested the combination as maintenance therapy in patients whose extensive-stage small cell lung cancer had not progressed after initial Imfinzi and chemotherapy, CNBC reports. Adding Amgen’s Imdelltra to AstraZeneca’s Imfinzi reduced the risk of death by 58% versus Imfinzi alone, a finding Reuters also reported. CNBC notes the study did not compare the combination with other first-line treatment approaches.